The timeline shows Eli Lilly's number of employees from 2013 to 2024. In 2024, the company's number of employees stood at some ** thousand.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

This statistic depicts the spending on research and development by Eli Lilly and Company, shown as a share of revenue from 2010 to 2024. In 2024, the company spent some 24 percent of its revenues on R&D purposes. Eli Lilly and Company is an international pharmaceutical company, headquartered in Indianapolis, Indiana.

This statistic reveals the expenditure of pharmaceutical company Eli Lilly and Company on research and development from 2007 to 2024. In 2024, expenditure on research and development came to a record-high of almost 11 billion U.S. dollars. Eli Lilly and Company is an international pharmaceutical company, headquartered in Indianapolis, Indiana.

Financial overview and grant giving statistics of Eli Lilly & Co Master Trust For Employee Benefits

Financial overview and grant giving statistics of Eli Lilly And Company Foundation

The timeline shows Eli Lilly's capital expenditures from 2013 to 2024. In 2024, the company's capital expenditures amounted to 5.06 billion U.S. dollars. Eli Lilly is one of the global leading pharmaceutical companies and one of the world's largest manufacturers of diabetes medications.

Financial overview and grant giving statistics of Eli Lilly Company Master Trust For Post Retirement Medical Benefi

Financial overview and grant giving statistics of Eli Lilly for the Rector Wardens and Vestrymen of Christ Church

The total equity of Eli Lilly with headquarters in the United States amounted to ***** billion U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total increase by approximately **** billion U.S. dollars. The trend from 2020 to 2024 shows, furthermore, that this increase happened continuously.

Eli Lilly is strategizing to increase Zepbound sales as they face supply chain difficulties, impacting their revenue outlook.

The timeline shows Eli Lilly's marketing, selling, and administrative expenses from 2013 to 2024. In 2024, the expenses amounted to 8.6 billion U.S. dollars. Eli Lilly is one of the global leading pharmaceutical companies and one of the world's largest manufacturers of diabetes medications.

The global Oral Erectile Dysfunction (ED) Therapeutic market is poised for significant expansion, projected to reach an estimated $12,500 million by 2025 and exhibiting a robust Compound Annual Growth Rate (CAGR) of 7.5% throughout the forecast period of 2025-2033. This impressive growth is primarily fueled by a confluence of demographic shifts and evolving healthcare landscapes. The increasing prevalence of age-related health concerns, particularly among men over 50, directly correlates with a higher incidence of erectile dysfunction. Furthermore, a growing awareness and reduced stigma surrounding ED are empowering individuals to seek timely medical intervention, thereby driving demand for effective oral treatments. Advancements in pharmaceutical research and development are continually introducing novel and more effective therapeutic options, further stimulating market growth. The market is segmented by application, with "Age 50" representing a dominant segment due to the aging global population. The "Protein" and "Hormones" types are key therapeutic categories, with ongoing research exploring their efficacy and innovative delivery methods. The market's trajectory is further shaped by several key drivers, including the escalating rates of chronic diseases like diabetes and cardiovascular conditions, which are intrinsically linked to ED. Improved diagnostic tools and an increased focus on men's health initiatives by healthcare providers are also contributing to market expansion. However, certain restraints, such as the high cost of some advanced oral ED therapeutics and the persistent, albeit diminishing, social stigma associated with sexual health issues, could temper the growth in specific regions or demographic groups. Key players like Eli Lilly, Pfizer, and Bayer are at the forefront of innovation, investing heavily in R&D to introduce next-generation treatments and expand their market reach. The Asia Pacific region, with its rapidly growing economies and increasing healthcare expenditure, is anticipated to witness substantial growth, alongside the established markets of North America and Europe. The focus on improving patient access and developing more accessible treatment options will be critical for sustained market dominance. This comprehensive report offers an in-depth analysis of the global Oral Erectile Dysfunction (OED) Therapeutic market, providing strategic insights crucial for stakeholders navigating this dynamic sector. The study spans a significant period, encompassing the Historical Period (2019-2024), Base Year (2025), and extending through an extensive Forecast Period (2025-2033), with a detailed look at the Study Period (2019-2033). The market is meticulously segmented to offer granular understanding and actionable intelligence.

Study reveals Mounjaro, Eli Lilly's diabetes drug, offers significant heart health benefits, reducing cardiovascular risks and mortality in Type 2 diabetes patients.

Eli Lilly remains cautious about using an FDA fast-track voucher for its oral weight-loss drug orforglipron, preferring a standard global filing strategy despite its blockbuster potential.

This graph shows the revenue of Eli Lilly and Company from 2022 to 2024, sorted by region. Eli Lilly is one of the top global pharmaceutical companies and a world leader in diabetes medicines. In 2024, the company generated some *** billion U.S. dollars of its revenue in Japan, an increase compared to 2023.

Discover the explosive growth of the monoclonal antibodies market for Alzheimer's disease, projected to reach $5.272 billion by 2025 with a 65.4% CAGR. Explore market drivers, trends, restraints, and key players like Biogen and Eli Lilly. Get the latest insights on this rapidly evolving therapeutic area.

Discover the latest market analysis on targeted Alzheimer's drugs, revealing a rapidly expanding market driven by an aging population and innovative treatment development. Explore market size, growth projections (2025-2033), regional trends, and key players shaping this crucial sector.

Discover the booming osteo peptide market! Our comprehensive analysis reveals a projected $2.8 billion market by 2033, driven by aging populations and growing demand for effective bone & joint treatments. Explore market trends, key players (Eli Lilly, Biocon, etc.), and future growth potential.